(Albany, United States) As per DelveInsight’s assessment, globally, the Hepatorenal Syndrome Pipeline constitutes 3+ key companies continuously working towards developing 3+ Hepatorenal Syndrome Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Hepatorenal Syndrome Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hepatorenal Syndrome NDA approvals (if any), and product development activities comprising the technology, Hepatorenal Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

To explore more information on the latest breakthroughs in the Hepatorenal Syndrome Pipeline treatment landscape of the report, click here @ Hepatorenal Syndrome Pipeline Outlook

 

Key Takeaways from the Hepatorenal Syndrome Pipeline Report

• DelveInsight’s Hepatorenal Syndrome Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline treatment therapies.
• The leading companies are working in the Hepatorenal Syndrome market include Noorik Biopharmaceuticals, Cumberland Pharmaceuticals, BioVie, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc., Novartis, and others.
• Promising Hepatorenal Syndrome Pipeline Therapies in the various stages of development include Ifetroban Injection, Terlipressin, OCE-205, and others.
• On August 2023, Ocelot Bio Inc. announced a study of phase 2 clinical trials for OCE-205. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.

 

Hepatorenal Syndrome Overview

Hepatorenal syndrome is a serious complication of liver cirrhosis with a critically poor prognosis. The pathophysiological hallmark is severe renal vasoconstriction, resulting from complex changes in splanchnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators.

 

For further information, refer to the detailed Hepatorenal Syndrome Unmet Needs, click here for Hepatorenal Syndrome Ongoing Clinical Trial Analysis

 

Hepatorenal Syndrome Emerging Drugs Profile

 

• Ambrisentan: Noorik Biopharmaceuticals

Ambrisentan, a small molecule, is a well-characterised endothelin receptor antagonist. Ambrisentan has the ability to block the effects of endothelin on both the ETA and ETB receptors. However, the blockade of each receptor occurs at different concentrations of Ambrisentan in blood: Ambrisentan blocks the ETA receptor at significantly lower concentrations than those required to block the ETB receptor. The drug is in phase 2 of clinical trials for the treatment of Hepatorenal Syndrome.

 

• Ifetroban: Cumberland Pharmaceuticals

Ifetroban is a potent antagonist of the thromboxane prostanoid (TPr) receptor, which has various functions including smooth muscle contraction, platelet aggregation and inflammation. Preclinical work on this molecule demonstrated that blocking TPr with ifetroban improves cardiac survival while increasing cardiac output in multiple animal models. The drug is in phase 2 of clinical trials for the treatment of Hepatorenal Syndrome.

 

Hepatorenal Syndrome Pipeline Therapeutics Assessment

There are approx. 3+ key companies which are developing the therapies for Hepatorenal Syndrome. The Hepatorenal Syndrome companies which have their Hepatorenal Syndrome drug candidates in the mid to advanced stage, i.e. phase II include, Noorik Biopharmaceuticals and others.

 

Request a sample and discover the recent advances in Hepatorenal Syndrome Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Hepatorenal Syndrome Segmentation

 

Hepatorenal Syndrome Drugs and Companies

• Ifetroban Injection: Cumberland Pharmaceuticals
• Terlipressin: Mallinckrodt
• OCE-205: Ocelot Bio Inc.

 

Hepatorenal Syndrome Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type 

 

Some of the Companies in the Hepatorenal Syndrome Therapeutics Market include-

Noorik Biopharmaceuticals, Cumberland Pharmaceuticals, BioVie, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc., Novartis, and others.

 

Dive deep into rich insights for drugs for Hepatorenal Syndrome Pipeline, click here @ Hepatorenal Syndrome Unmet Needs and Analyst Views

 

Scope of the Hepatorenal Syndrome Pipeline Report

• Coverage- Global
• Companies- Noorik Biopharmaceuticals, Cumberland Pharmaceuticals, BioVie, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc., Novartis, and others.
• Therapies- Ifetroban Injection, Terlipressin, OCE-205, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Hepatorenal Syndrome Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Hepatorenal Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatorenal Syndrome – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Hepatorenal Syndrome Collaboration Deals
9. Late- Stage Products (Phase III)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Ambrisentan: Noorik Biopharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Hepatorenal Syndrome Key Companies
17. Hepatorenal Syndrome Key Products
18. Hepatorenal Syndrome- Unmet Needs
19. Hepatorenal Syndrome- Market Drivers and Barriers
20. Hepatorenal Syndrome- Future Perspectives and Conclusion
21. Hepatorenal Syndrome Analyst Views
22. Hepatorenal Syndrome Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services